| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

13-15 January 2025

14th Annual LifeSci Advisors Corporate Access Event

Beacon Grand Hotel in San Francisco

CA

United States

12 January 2025

8th Sachs Annual Neuroscience Innovation Forum

Marines’ Memorial Club in San Francisco

CA

United States

9 January 2025

ORYZON to provide corporate progress updates at several events in January-February

11 December 2024

Video: Edison Group - executive interview with our CEO

2 December 2024

ORYZON continues to strengthen its patent portfolio for vafidemstat

12 November 2024

Video: Watch an interview with our CEO at BIO-Europe

31 October 2024

ORYZON receives Notice of allowance for patent on novel technology for measuring LSD1 target engagement

24 October 2024

ORYZON reports financial results and corporate update for quarter ended September 30, 2024

14 October 2024

ORYZON announces formal grant of key European patent for vafidemstat

1 October 2024

Oryzon Webcast to Discuss FDA Feedback on End-of-Phase II Meeting and Plans for PORTICO-2 Phase III Trial with vafidemstat in Borderline Personality Disorder

Pagination

First page «
Previous page ‹
Page 1
Page 2
Current page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel